Introduction
Illudins are sesquiterpenoid compounds derived from the mushroom Omphalotus illudens and related species of basidiomycetes, whose chemical structure is different from known chemotherapeutic agents. [1] [2] [3] The illudins are preferentially cytotoxic in vitro to a variety of hematopoietic and solid tumor cells at nano-to picomolar concentrations. 4, 5 In contrast, normal bone marrow progenitors or fibroblasts are relatively resistant to illudins and require micromolar concentrations for equivalent in vitro cytotoxicity. 4 MGI 114 is known to produce an unusual type of DNA damage which induces apoptosis in some tumor cells, but the nature of the lesions have not been clearly defined. 6 Cell lines deficient in the ERCC2 and ERCC3 DNA repair helicases are minimally sensitive to conventional anticancer agents, but are relatively hypersensitive to illudins, 6 suggesting repair of illudin-induced DNA damage requires the early action of the helicases before repair can proceed.
Although Illudin S (Figure 1 ) proved too toxic for effective use in vivo, 4 we developed a class of illudin-derived agents, called dehydroilludins, with an improved in vivo therapeutic index against experimental tumors as compared to the parent compound. 7 A second class of analogs called acylfulvenes were even more effective in lung xenograft models. 8 The acylfulvene class of analogs are covered by US Patents 5,439,936 and 5,523,490, pending US Patent application claims, European Common Patent 0565511, pending European Common patent application claims, and foreign patent application claims. One acylfulvene analog, MGI 114 (6-hydroxymethylacylfulvene or HMAF) (Figure 1 ), demonstrated marked efficacy in a variety of solid tumor xenograft models including an mdr1/gp170 expressing tumor xenograft. Illudins were originally envisaged as anti-leukemic agents, specifically myeloid leukemias, due to the finding that hematopoietic tumor cells were markedly sensitive to illudins whereas normal bone marrow progenitors were relatively resistant to illudins. 4, 5 The currently scheduled phase II human trials, however, involve only solid tumors (breast, lung, colon, ovarian, pancreatic, pancreas, etc) and not leukemias. This shift in emphasis occurred due to the preclinical findings of a marked efficacy by MGI 114 against a variety of solid tumor xenografts.
9-11 Therefore, we wished to obtain preclinical data on MGI 114 to determine whether this semi-synthetic illudin analog would be efficacious against myeloid leukemia xenografts.
A recent report noted a strong synergistic in vitro cytotoxic
Figure 1
Structures of the four illudin derivatives used in this study.
action between MGI 114 and topotecan in a panel of pediatric tumor cells lines. 12 An excellent in vivo synergistic action was noted between MGI 114 and topotecan in the MV522 lung carcinoma xenograft 13 and between MGI 114 and irinotecan in the HT-29 colon tumor xenograft.
14 Therefore, we determined if a synergistic action against human myeloid leukemic cells would occur in vitro and in vivo between MGI 114 and a topoisomerase I inhibitor.
Materials and methods

Athymic mice
Balb/c nu/nu 4-week-old female mice weighing 18-22 g were obtained from Simonsen (Gilroy, CA, USA) and maintained in the athymic mouse colony of the University of California, San Diego, under pathogen-free conditions using HEPA filter hoods. The animals were provided with sterilized food and water ad libitum in groups of four in plastic cages vented with polyester fiber filter covers. Clean, sterilized gowns, gloves, masks, shoe and hood covers were worn by all personnel handling the animals. All studies were conducted in accordance with the guidelines of the NIH 'Guide for Care and Use of Animals', and the University of California, San Diego guidelines for assessing illness and morbidity in rodents used in studies involving experimental neoplasia. All studies were approved by the University Institutional Animal Care and Use Committee (Protocol 3-006-3).
Cell lines, culture conditions and cytotoxicity assays
The HL60/MRI promyelocytic leukemia line, which can be maintained in athymic nude mice, 15 was obtained from Dr Theodore R Breitman (NCI, Bethesda, MD, USA). 16, 17 The HL60/MRI line was maintained in antibiotic-free RPMI 1640 media (Mediatech, Herndon, VA, USA) supplemented with 10% (v/v) fetal bovine serum plus 2 mM glutamine in a humidified 5% CO 2 incubator at 37°C.
Briefly, the in vitro cytotoxic effects of each drug was determined individually by adding various concentrations to cultures of HL60/MRI cells, and determining cell growth 48 h later. Viability of HL60/MRI cells was assessed by trypan blue exclusion. 4, 5 The in vitro synergy studies were performed by adding the desired two drugs together at various concentrations, but always maintaining a fixed ratio of drug A to drug B within an individual experiment. 18, 19 Results were compared to control cultures (no drug) and to cultures in which only an individual drug was added at identical concentrations. Determination of whether a given drug combination at a given concentration and ratio was performed by the median-effect principal and the dose-response fractional product principal (see statistical analysis).
Drugs
Anticancer drugs were obtained from the UCSD Medical Center Pharmacy and formulated with the supplied diluent according to directions provided by the manufacturer. Drugs included: paclitaxel (Taxol; Bristol-Meyers-Squibb, Princeton, NJ, USA) reconstituted in Cremophor EL; mitomycin C (Mutamycin; Bristol-Meyers-Squibb) reconstituted in sterile water; topotecan (Hycamtin, Smith-Kline Beecham, PhiladelLeukemia phia, PA, USA) reconstituted in sterile saline. Mitomycin C was included as this agent originally demonstrated activity towards myeloid leukemias. 20 Vehicle controls were performed where appropriate. Illudin analogs were prepared for in vivo testing by dissolving at maximum solubility in a sterile 40% DMSO/normal saline mixture and diluted to appropriate concentrations with sterile 10% DMSO/normal saline. 8 The maximum tolerated dose (MTD) for the experimental illudinderived agents and the standard chemotherapeutic agents in this strain of mice was previously determined and defined as the maximum dose administered for 3 weeks on a given schedule that produces a weight loss of Ͻ10%.
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Illudin isolation and analog synthesis
The Illudin S, Dehydroilludin M, and Acylfulvene analog were prepared as described previously. 3, 7, 21, 22 The novel MGI 114 analog was synthesized from the Acylfulvene analog 23 using formaldehyde. The synthesis and spectroscopic data for MGI 114 is described in detail elsewhere. 23 Structures of the illudin analogs are provided ( Figure 1 ).
In vivo evaluation using the HL60/MRI xenograft model
Mice were randomized into treatment groups of eight to 12 animals each. Each animal was earmarked and followed individually throughout the experiment. The mice received s.c. injections of 8 to 10 million HL60/MRI cells over the shoulder. Ten days after implantation of the HL60/MRI cells the animals received the desired drug and dosage. Tumor size was measured in two perpendicular diameters and tumor weight estimated according to the formula w = [(width) 2 × length/2]. 24 Relative weights (RW) were calculated to standardized variability in tumor size amongst test groups at initiation of the treatment by using the formula RW = Wt/Wi, where Wi is the tumor weight for a given animal at the beginning of drug treatment and Wt is tumor weight at a subsequent time t. 24 A pilot study was performed using the combination of . MTD of MGI 114 and . MTD of topotecan to ensure that severe additive toxicity did not exist between MGI 114 and topotecan. After determining that additive toxicity did not exist between MGI 114 and and topotecan, a dose-response study was performed to determine the maximum amount of MGI 114 and topotecan that could be co-administered without producing drug toxicity.
Statistical analysis and determination of synergistic activity
To compare the relative tumor weights between the groups of animals, ANOVA followed by Tukey-Kramer multiple comparison post-ANOVA analysis was performed. Comparison of survival curves between groups of animals was performed using the method of Kaplan and Meier. 25 Probability values less than 0.05 were considered statistically significant. The relative tumor weight data and life span data were analyzed using Instat (version 2.02) and Prism (version 2.0) software packages (Graph Pad, La Jolla, CA, USA).
To determine if synergy existed between MGI 114 and the topoisomerase inhibitor topotecan, we used the median-effect principle by Chou 18, 19 to determine dose-effect parameters for two drugs individually and for their mixtures at different combinations. This method was chosen because it analyzes the shape of the drug dose-response curves for each drug, combinations of drugs, and quantitates synergism/antagonism at different concentrations.
To determine if synergy existed between MGI 114 and the topoisomerase inhibitor topotecan, we used both the medianeffect principle by Chou 18, 19 to determine dose-effect parameters for two drugs individually and for their mixtures at different combinations, and the more traditional dose-response fractional product of Webb. 26 A review of 16 various methods to evaluate pharmacologic synergy identified these two techniques as among the most common means of determining whether cooperative pharmacologic interaction exists between various agents. 27 The median-effect method, unlike the fractional product method, analyzes the shape of the drug dose-response curves for each drug, combinations of drugs, and allows quantification of synergism or antagonism at different concentrations. 18, 27 Median-effect computer software (CalcuSyn for Windows, Biosoft; Ferguson, MO, USA) was used to generate the isoeffective dose (Dx) values which are used to generate the combination index (CI), where a CI value of Ͻ1, =1 and Ͼ1 indicates synergism (ie the effect of drug combination is greater than anticipated from the additive effect of the individual agents), additive effect, and antagonism respectively.
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Results
The efficacy of the four illudin-derived analogs (Illudin S, Dehydroilludin M, Acylfulvene, MGI 114) against the HL60/MRI promyelocytic leukemia xenograft model was first compared to the conventional agents mitomycin C and taxol. The rapid growth of the HL60/MRI tumor caused mortality in control animals between days 21 and 26. The conventional agents mitomycin C and paclitaxel inhibited tumor growth (P Ͻ 0.01) (Figure 2 ) and prolonged life span (P Ͻ 0.02). The novel analog MGI 114 was more effective at inhibiting HL60/MRI tumor growth (TGI = 73%, P Ͻ 0.001) than either conventional agent and prolonging life span (P Ͻ 0.001). The Acylfulvene analog displayed mild tumor inhibition (P Ͻ 0.05) and also prolonged life span (P Ͻ 0.001), The Dehydroilludin M and the Illudin S analogs had minimal effect on tumor growth rate but were capable of prolonging life span (P Ͻ 0.02) (data not shown). There was no evidence in any individual animal in any group, including the MGI 114-treated group, of tumor regression.
Three previous reports noted excellent synergistic cytotoxic action between MGI 114 and topoisomerase I interactive agents both in vitro and in two human solid tumor xenografts, as well as against a panel of pediatric tumor cells lines.
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Therefore, we determined if a synergistic action against human myeloid leukemic cells would occur in vitro and in vivo between MGI 114 and the topoisomerase I inhibitor topotecan.
Topotecan was chosen as the desired topoisomerase I interactive agent because we wished to compare the in vitro results with those obtained in the xenograft studies. Irinotecan was not used because the agent is not active in vitro. The Irinotecan active metabolite SN38 must be used for cell culture studies, but we were unable to obtain the compound.
The potential synergistic activity of MGI 114 in combination with topotecan was determined in vitro using a continuous 48-h exposure period. As a comparison, the inter- action between MGI 114 and cisplatin was also studied. Analysis by the median-effect principle revealed a CI range of р0.2 which is classified as a strong or 4+ synergism 18, 19 for the MGI 114/topotecan combination ( Figure 3) . Analysis by the fractional product method for Webb 26 classified all data points as synergistic (data not shown). In contrast, MGI 114 and cisplatin combinations were only additive when CI values were у1.0. A pilot in vivo study indicated that topotecan at MTD or . MTD was capable of inhibiting tumor growth, and the inhibition of growth exceeded that noted with MGI 114 alone ( Figure 4) . It is noteworthy that no animal receiving either the MTD of topotecan or MGI 114 individually displayed any evidence of tumor regression. When the MGI 114 and the topotecan were co-administered at the nontoxic dose of . MTD for each drug, there was tumor regression in all eight animals ( Figure 4) . Four of the eight animals (50%) were alive at day 45 without evidence of tumor by palpation, while no animals were alive in other groups (P Ͻ 0.01).
A larger study was then performed to determined the maximum doses of MGI 114 and topotecan that could be utilized in combination. For this study the amount of HL60/MRI cells injected s.c. was reduced from 10 to 8 million due to the extremely rapid growth of the tumor. Both drugs were administered i.p. five times per week for 3 weeks. Animals receiving 2 of MTD of each drug displayed marked tumor regression, but developed drug toxicity after 9 days of therapy (body weight loss у15%), and drug treatment was discontinued ( Figure 5 ). Animals receiving either 0 MTD of each drug, or . MTD of each drug, displayed marked tumor regression. In contrast, tumor regression was again not noted in any animal receiving either the MTD of MGI 114 alone or the MTD of topotecan alone, although inhibition of tumor growth was observed. While administration of agents individually did again significantly prolong life span (MGI 114 ILS 72%, P Ͻ 0.01 vs controls; topotecan ILS 75%, P Ͻ 0.01 vs controls), the combination therapy was again more effective (0 MTD of each agent ILS 118%, P Ͻ 0.0006 vs controls, or MGI 114 MTD group, or topotecan MTD group; . MTD of each agent ILS 114%, P Ͻ 0.0006 vs controls, or MGI 114 MTD group, or topotecan MTD group).
Discussion
Both the in vitro and in vivo studies revealed a marked synergistic action between MGI-114 and topotecan. The in vitro synergistic CI value, when compared to previous synergistic studies involving topotecan, is very high. Previous investigations on the potential interaction between topotecan and
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Figure 5
Dose-related response of combination MGI 114 and topotecan therapy against the HL60/MRI promyelocytic leukemia xenograft. Control animals received 20% DMSO/NS (), MGI 114 at 7 mg/kg (̆), topotecan at the MTD of 1. antimetabolites, antimicrotubule, and DNA alkylating agents 28, 29 detected a less than additive effect; CI у 1, considered a −1 or −2 effect as defined by Chou. 18, 19 A mild slight or nearly additive effect (CI values ranged from 0.8 to 1.0, +1 or ± effect) was noted with combinations of topotecan and cisplatin. 28, 29 The combination of MGI-114 and topotecan, however, produced a 4+ to 5+ synergism (CI р 0.3 at all concentrations tested). In contrast, there was no synergistic activity noted with combinations of MGI 114 and cisplatin, which is similar to what was noted with topotecan and cisplatin combinations. 28, 29 The HL60/MRI xenograft is a fairly stringent model for determining drug response. None of the four experimental illudin-derived agents (Illudin S, Dehydroilludin M, Acylfulvene, MGI 114) or the three conventional anticancer agents (Taxol, mitomycin C, topotecan) were capable of inducing tumor regression at their respective MTD in any individual animal (Figures 2 and 5 ). The strong synergistic activity between MGI 114 and topotecan allowed for administration of subtoxic doses for both agents, while resulting in a marked anti-leukemic effect. Indeed, co-administration of both agents at the nontoxic dose of . MTD resulted in a 50% 'cure' rate for HL60/MRI tumor-bearing mice. In contrast, administration of the MTD for either agent individually produced only growth delay, without evidence of tumor regression in any animal. Since co-administration of doses higher than 0 MTD for each agent resulted in drug toxicity, as evidenced by weight loss, there must be some additive toxicity for the two agents. However, the synergistic beneficial effect of co-administration of the agents surpasses the adverse toxic effect, as evidenced by the ability to eliminate tumors in 50% of the animals without producing drug toxicity.
The molecular basis for cooperative drug interaction between MGI 114 and topotecan remains unclear. This is in Leukemia part because the exact mechanism of action of MGI-114 is unknown. MGI 114 is known to produce an unusual type of DNA damage 6 and produce apoptosis in some tumor cells, 30 but the nature of the lesions have not been clearly defined. It is likely the synergistic effect arises because inhibition of topoisomerase I affects the ability of HL60/MRI cells to repair MGI-114 induced DNA damage. The marked difference in CI values for the topotecan/MGI-114 combination as compared to topotecan and other DNA damaging agent combinations (such as cisplatin) 31 is supportive of our early findings that illudins produce an unusual type of DNA damage and some DNA helicase-deficient cells are highly sensitive to these toxins. Note that these illudin-derived agents do not have to function as direct enzyme inhibitors (actually inhibit enzymatic activity), but only produce DNA damage that is difficult for the enzymes to repair. 32 Previous studies have noted that the anti-leukemic effect of topotecan in murine leukemic xenograft studies correlates well with the activity noted in subsequent human trials. 33 The dose of topotecan we administered to the mice of 2.25 mg/m 2 is nearly identical to the recommended dose for humans of 2 mg/m 2 . 34 The dose of MGI 114 administered to the mice of 10.5 mg/m 2 is also nearly identical to the current phase II human dose of 11 mg/m 2 , at which anticancer activity is occurring. 35 Thus, it is plausible that the synergistic action we noted between MGI 114 and topotecan will also be noted in human trials. In summary, our results support further clinical and in vitro investigation into both the anti-myeloid leukemic activity of MGI-114, and the cooperative pharmacologic interaction between MGI-114 and topoisomerase I inhibitors.
